Tailoring the degradation kinetics of mesoporous silicon structures through PEGylation.

Injectable and implantable porosified silicon (pSi) carriers and devices for prolonged and controlled delivery of biotherapeutics offer great promise for treatment of various chronic ailments and acute conditions. Polyethylene glycols (PEGs) are important surface modifiers currently used in clinic mostly to avoid uptake of particulates by reticulo-endothelial system (RES). In this work we show for the first time that covalent attachment of PEGs to the pSi surface can be used as a means to tune degradation kinetics of silicon structures. Seven PEGs with varying molecular weights (245, 333, 509, 686, 1214, 3400, and 5000 Da) were employed and the degradation of PEGylated pSi hemispherical microparticles in simulated physiological conditions was monitored by means of ICP-AES, SEM, and fluorimetry. Biocompatibility of the systems with human macrophages in vitro was also evaluated. The results clearly indicate that controlled PEGylation of silicon microparticles can offer a sensitive tool to finely tune their degradation kinetics and that the systems do not induce release of proinflammatory cytokines IL-6 and IL-8 in THP1 human macrophages.

[1]  Michael J Sailor,et al.  The Compatibility of Hepatocytes with Chemically Modified Porous Silicon with Reference to in Vitro Biosensors , 2022 .

[2]  Mauro Ferrari,et al.  The association of silicon microparticles with endothelial cells in drug delivery to the vasculature. , 2009, Biomaterials.

[3]  F. Dosio,et al.  Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential , 2006, International journal of nanomedicine.

[4]  Mauro Ferrari,et al.  Application of physicochemically modified silicon substrates as reverse-phase protein microarrays. , 2009, Journal of proteome research.

[5]  L. Canham.  Bioactive silicon structure fabrication through nanoetching techniques , 1995 .

[6]  P. Chow,et al.  A novel approach to brachytherapy in hepatocellular carcinoma using a phosphorous32 (32P) brachytherapy delivery device--a first-in-man study. , 2007, International journal of radiation oncology, biology, physics.

[7]  H. Merkle,et al.  PEGylation as a tool for the biomedical engineering of surface modified microparticles. , 2008, Journal of pharmaceutical sciences.

[8]  J. Buriak,et al.  LEWIS ACID MEDIATED FUNCTIONALIZATION OF POROUS SILICON WITH SUBSTITUTED ALKENES AND ALKYNES , 1998 .

[9]  Q. Nguyen,et al.  Fluocinolone acetonide intravitreal sustained release device – a new addition to the armamentarium of uveitic management , 2007, International journal of nanomedicine.

[10]  M. Annicchiarico-Petruzzelli,et al.  Fibroblast growth and polymorphonuclear granulocyte activation in the presence of a new biologically active sol–gel glass , 1997, Journal of materials science. Materials in medicine.

[11]  M. Ghadiri,et al.  A porous silicon-based optical interferometric biosensor. , 1997, Science.

[12]  B. Basu.  Critical heat transfer analysis of pulsed laser melting of pure metals , 1991 .

[13]  L L Hench,et al.  Toxicology and biocompatibility of bioglasses. , 1981, Journal of biomedical materials research.

[14]  K. Leslie,et al.  Biphasic cellular and tissue response of rat lungs after eight-day aerosol exposure to the silicon dioxide cristobalite. , 1989, The American journal of pathology.

[15]  D. Kiel,et al.  Dietary silicon intake and absorption. , 2002, The American journal of clinical nutrition.

[16]  Michael J. Sailor,et al.  Polymer Replicas of Photonic Porous Silicon for Sensing and Drug Delivery Applications , 2003, Science.

[17]  E M Carlisle,et al.  Silicon: A Possible Factor in Bone Calcification , 1970, Science.

[18]  Mauro Ferrari,et al.  Controlled-release microchips , 2006, Expert opinion on drug delivery.

[19]  Mauro Ferrari,et al.  Mesoporous silicon particles as a multistage delivery system for imaging and therapeutic applications. , 2008, Nature nanotechnology.

[20]  Mauro Ferrari,et al.  Nanomedicine—Challenge and Perspectives , 2009 .

[21]  Volker Lehmann,et al.  Porous silicon formation: A quantum wire effect , 1991 .

[22]  V. Kolb‐Bachofen.  Uptake of toxic silica particles by isolated rat liver macrophages (Kupffer cells) is receptor mediated and can be blocked by competition. , 1992, The Journal of clinical investigation.

[23]  V. Lehto,et al.  Mesoporous silicon microparticles for oral drug delivery: loading and release of five model drugs. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[24]  Mauro Ferrari,et al.  Physicochemically modified silicon as a substrate for protein microarrays. , 2007, Biomaterials.

[25]  Michael J. Sailor,et al.  Compatibility of Primary Hepatocytes with Oxidized Nanoporous Silicon , 2001 .

[26]  A. Uhlir.  Electrolytic shaping of germanium and silicon , 1956 .

[27]  L. Canham,et al.  Derivatized Mesoporous Silicon with Dramatically Improved Stability in Simulated Human Blood Plasma , 1999 .